Olema Pharmaceuticals, Inc. (OLMA) Ownership
OLMA ownership summary
as of October 18, 2026- Institutions
- 119.7% of shares outstanding
- Insiders
- 1.76% of shares outstanding
- Shares outstanding
- 87.5M
- Float
- 59.2M shares available to trade
- Short interest
- 20.40% 14.7M shares short
- Days to cover
- 11.88 short interest down 8.5% vs prior month
- Institutions 119.73%
- Insiders 1.76%
OLMA top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | FMR Inc | 13.88% | 12.1M | $79.9M | +1.8M (+16.9%) | June 30, 2026 |
| 2 | Paradigm Biocapital Advisors LP | 9.91% | 8.7M | $57.1M | +650,000 (+8.1%) | June 30, 2026 |
| 3 | HHG PLC | 8.12% | 7.1M | $46.8M | +398,294 (+5.9%) | March 31, 2026 |
| 4 | Jupiter Topco LLC | 8.11% | 7.1M | $46.7M | +7.1M (0.0%) | June 30, 2026 |
| 5 | Bain Capital Life Sciences Investors, LLC | 8.10% | 7.1M | $46.6M | −387,989 (−5.2%) | June 30, 2026 |
| 6 | BlackRock Inc | 7.67% | 6.7M | $44.2M | +1.1M (+18.8%) | June 30, 2026 |
| 7 | Bvf Inc | 6.05% | 5.3M | $34.8M | — | June 30, 2026 |
| 8 | Siren, L.L.C. | 5.55% | 4.9M | $32.0M | +100,000 (+2.1%) | June 30, 2026 |
| 9 | State Street Corp | 4.93% | 4.3M | $28.4M | +378,227 (+9.6%) | June 30, 2026 |
| 10 | Vanguard Capital Management, LLC | 3.82% | 3.3M | $22.0M | +257,700 (+8.4%) | June 30, 2026 |
| 11 | Logos Global Management LP | 3.67% | 3.2M | $21.1M | — | June 30, 2026 |
| 12 | Franklin Templeton Inc | 2.69% | 2.3M | $15.5M | +1.1M (+92.8%) | June 30, 2026 |
| 13 | Cormorant Asset Management, LLC | 2.46% | 2.1M | $14.1M | −1.8M (−44.9%) | June 30, 2026 |
| 14 | Morgan Stanley - Brokerage Accounts | 2.09% | 1.8M | $12.1M | +616,579 (+50.7%) | June 30, 2026 |
| 15 | Geode Capital Management, LLC | 2.08% | 1.8M | $12.0M | +274,612 (+17.8%) | June 30, 2026 |
| 16 | Vanguard Portfolio Management, LLC | 1.90% | 1.7M | $10.9M | +1.1M (+180.5%) | June 30, 2026 |
| 17 | The Goldman Sachs Group Inc | 1.79% | 1.6M | $10.3M | +522,390 (+50.0%) | June 30, 2026 |
| 18 | Deep Track Capital, LP | 1.71% | 1.5M | $9.9M | +1.5M (0.0%) | June 30, 2026 |
| 19 | Dimensional Fund Advisors, Inc. | 1.62% | 1.4M | $9.3M | +334,099 (+30.9%) | June 30, 2026 |
| 20 | Lightspeed Management Co LLC | 1.55% | 1.4M | $8.9M | — | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 15 holders added 17.1M shares and 2 cut 2.1M.
OLMA top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.98% | 2.6M | $17.2M | — | August 31, 2026 |
| 2 | State Street® SPDR® S&P® Biotech ETF | 2.47% | 2.2M | $14.2M | −41,250 (−1.9%) | September 30, 2026 |
| 3 | iShares Russell 2000 ETF | 2.32% | 2.0M | $13.4M | −23,424 (−1.1%) | September 30, 2026 |
| 4 | Fidelity Select Health Care | 1.92% | 1.7M | $11.1M | — | August 31, 2026 |
| 5 | Strategic Advisers Fidelity US TtlStk | 1.88% | 1.6M | $10.8M | +10,300 (+0.6%) | August 31, 2026 |
| 6 | Franklin Biotechnology Discv A(acc)USD | 1.15% | 1.0M | $6.6M | — | August 31, 2026 |
| 7 | Fidelity Stock Selector Small Cap | 1.04% | 907K | $6.0M | — | July 31, 2026 |
| 8 | Janus Henderson Hrzn Biotec E2 USD | 1.00% | 874K | $5.8M | −3,266 (−0.4%) | June 30, 2026 |
| 9 | Fidelity Small Cap Index | 0.98% | 856K | $5.6M | +6,632 (+0.8%) | July 31, 2026 |
| 10 | Fidelity Advisor Health Care I | 0.94% | 820K | $5.4M | — | August 31, 2026 |
| 11 | Fidelity Advisor Biotechnology I | 0.89% | 777K | $5.1M | — | August 31, 2026 |
| 12 | Franklin Small Cap Growth Adv | 0.79% | 694K | $4.6M | — | August 31, 2026 |
| 13 | Belfius Equities Cure C Cap | 0.77% | 671K | $4.4M | — | March 31, 2026 |
| 14 | Janus Henderson Global Life Sciences D | 0.75% | 659K | $4.3M | +997 (+0.2%) | August 31, 2026 |
| 15 | Janus Henderson Glb Life Scn I2 USD | 0.73% | 640K | $4.2M | +5,978 (+0.9%) | August 31, 2026 |
| 16 | Janus Global Life Science AUSD | 0.72% | 634K | $4.2M | +11,639 (+1.9%) | June 30, 2026 |
| 17 | Fidelity Select Biotechnology | 0.72% | 628K | $4.1M | — | August 31, 2026 |
| 18 | iShares Russell 2000 Value ETF | 0.70% | 616K | $4.1M | +934 (+0.2%) | September 30, 2026 |
| 19 | Franklin Biotechnology Discovery A | 0.65% | 569K | $3.7M | — | August 31, 2026 |
| 20 | Vanguard Explorer Inv | 0.64% | 558K | $3.7M | +557,806 (0.0%) | June 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
OLMA insider transactions
latest 18| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-04 | Shawnte Mitchell | Sell | $24.25 | 25,000 | $606,250 |
| 2026-03-03 | Shawnte Mitchell | Sell | $23.01 | 15,000 | $345,150 |
| 2026-01-20 | Cyrus Harmon | Sell | $26.88 | 10,000 | $268,800 |
| 2026-01-15 | Shane William Charles Kovacs | Sell | $28.73 | 100,000 | $2.9M |
| 2026-01-14 | Cyrus Harmon | Sell | $29.12 | 3,489 | $101,600 |
| 2026-01-13 | David C Myles | Sell | $27.60 | 50,000 | $1.4M |
| 2026-01-13 | Shane William Charles Kovacs | Sell | $28.01 | 3,822 | $107,054 |
| 2026-01-12 | David C Myles | Sell | $28.34 | 10,000 | $283,400 |
| 2025-12-23 | Naseem Zojwalla | Sell | $27.66 | 99,509 | $2.8M |
| 2025-12-22 | Cyrus Harmon | Sell | $28.53 | 2,881 | $82,195 |
| 2025-12-22 | Naseem Zojwalla | Sell | $28.04 | 100,000 | $2.8M |
| 2025-12-19 | David C Myles | Sell | $30.46 | 51,000 | $1.6M |
| 2025-12-19 | Ian T Clark | Sell | $29.73 | 264,800 | $7.9M |
| 2025-12-19 | Naseem Zojwalla | Sell | $28.20 | 70,000 | $2.0M |
| 2025-09-18 | Cyrus Harmon | Sell | $8.33 | 10,000 | $83,300 |
| 2025-09-18 | Cyrus Harmon | Sell | $8.32 | 3,086 | $25,676 |
| 2025-09-16 | Cyrus Harmon | Sell | $8.04 | 10,000 | $80,400 |
| 2025-09-16 | Cyrus Harmon | Sell | $8.08 | 1,914 | $15,465 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
OLMA shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns OLMA
Institutional investors own 119.7% of Olema Pharmaceuticals's shares and insiders 1.76%. The largest holder is FMR Inc with 13.88% of the shares (12.1M), as of June 30, 2026. Among the top 20 institutions, 15 added shares and 2 reduced their stake in the latest filings. Short interest is 20.40% of the float, or 11.88 days of average trading volume. The share count rose 2,943.9% since 2018.
Related: OLMA analyst forecast, OLMA key metrics. See the OLMA stock overview for the latest quote and news.
OLMA ownership FAQ
Who owns the most Olema Pharmaceuticals stock?
The largest shareholders of Olema Pharmaceuticals are FMR Inc (13.88%), Paradigm Biocapital Advisors LP (9.91%), HHG PLC (8.12%), Jupiter Topco LLC (8.11%), Bain Capital Life Sciences Investors, LLC (8.10%).
What percentage of Olema Pharmaceuticals is owned by institutions?
Institutions hold 119.7% of Olema Pharmaceuticals's shares outstanding; insiders hold 1.76%.
Which funds own Olema Pharmaceuticals?
The largest fund holders of Olema Pharmaceuticals are Vanguard MStar Total Stk Mkt Idx Invest (2.98%), State Street® SPDR® S&P® Biotech ETF (2.47%), iShares Russell 2000 ETF (2.32%), Fidelity Select Health Care (1.92%), Strategic Advisers Fidelity US TtlStk (1.88%).
What is Olema Pharmaceuticals's short interest?
14.7M shares of Olema Pharmaceuticals were sold short, 20.40% of the float; at the average daily volume it would take 11.88 days to cover.
Are insiders buying or selling Olema Pharmaceuticals?
Of the latest 18 reported insider transactions in Olema Pharmaceuticals (since September 16, 2025), 0 were purchases and 18 were sales.
How many shares of Olema Pharmaceuticals are outstanding?
Olema Pharmaceuticals has 87.5M shares outstanding, of which 59.2M are in the public float.